

**DH CIRCULAR No. 44/2017**  
DH 827/2017

**21 June 2017**

**Attention All:** Consultants  
Medical Officers  
Pharmacists  
Pharmacy Technicians  
Nurses

**Re: Mitomycin C 40mg Vials**

It is being brought to your attention that mitomycin C 40mg vials are now available on the Government Formulary List for in-patient use.

Mitomycin C 40mg vials are presented as powder for solution for injection to be used for bladder instillation and to be administered intravesically via Electromotive Drug Administration (EMDA).

Mitomycin C 40mg vials are protocol regulated by protocol 138 (Annex D) and can be prescribed by Consultant Urologists for superficial bladder tumours as per said protocol.

For your attention please.

Dr. Denis Vella Baldacchino  
Chief Medical Officer

## **Mitomycin C 40mg Vials**

(To be administered intravesically via Electromotive Drug Administration [EMDA])

**Prescriber criteria:** Consultant Urologist

### **In-patient use:**

#### **1. Neoadjuvant use prior to resection of superficial bladder tumours**

To be used as a perioperative single dose instillation before Transurethral Resection of Bladder Tumour (TURBT)

#### **2. Management of high risk superficial bladder tumours**

To be used either:

- in combination with BCG during the induction and maintenance course

OR

- on its own during the induction and maintenance course when BCG is not available (as a stop gap measure), or in patients who are either hypersensitive to BCG or have a past history of TB